CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced the initiation of a proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist. TRV734 is currently being evaluated as a potential maintenance therapy for opioid use disorder.
The study is funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. Trevena is providing TRV734 to NIDA Intramural Research Program scientists who are conducting the study.
“The opioid crisis remains a crippling public health issue, and multiple solutions are needed to tackle this urgent problem,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. “A novel mu-opioid receptor selective agonist such as TRV734 may have value as an alternative or complement to current treatments for opioid addiction, which are effective in some but not all people with opioid use disorder. We are excited to be working with NIDA to initiate this important proof-of-concept study.”
This is a randomized, double-blind, four-period, placebo- and positive-controlled study that will enroll approximately 50 opioid-dependent patients undergoing stable methadone maintenance therapy. The primary objective of the study is to assess the ability of TRV734 to reduce acute opioid craving symptoms, as measured by the Subjective Opioid Withdrawal Scale. The study will also evaluate whether TRV734 suppresses withdrawal signs using the Clinical Opioid Withdrawal Scale. Secondary outcomes will include assessments of safety and measures of neurocognitive changes.
Source: Trevena, Inc., 955 Chesterbrook Blvd, Suite 200, Chesterbrook PA 19087
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.